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Analysing the co-evolution of embedded regulatory capabilities in firms and the state: the 
case of South Africa’s medical device sector 
 




Regulatory authorities in developing economies not only face challenges regarding their own 
capabilities, but also have to grapple with heterogeneous levels of technological and 
innovation capabilities in firms. This paper draws from a firm-level analysis of internally 
created knowledge, externally sourced knowledge and firm heterogeneity among medical 
device manufacturers in South Africa to consider the corresponding evolution, development 
and deployment of regulatory capabilities in firms in their efforts to comply with the country’s 
health and allied products regulatory authority requirements. From this consideration, the 
paper explores possible broader adjustments in the country’s medical device sectoral system 
of innovation which would promote, nurture and embed the desired regulatory capabilities 
in firms to enable medical device firms to be locally and globally competitive and to contribute 
optimally to the country’s health sector objectives.  
 
Medical device industries based in developing countries are few and generally focused on the 
low-tech part of the sector. The diversity and scale of health challenges in developing 
countries make the role of medical devices even more significant but according to WHO 
(2012) only 13% of manufacturers are located in developing countries. In developing 
countries, over 95% of the medical devices in public hospitals are imported, with very limited 
local production (Malkin, 2007). Moreover, most of the medical devices are inappropriate for 
local needs and unable to be sustained with the lack of local infrastructure (Lustick and 
Zaman, 2011). For example, WHO (2016) conducted a detailed analysis of medical devices 
policies from four selected countries in Africa (Ethiopia, Nigeria, South Africa and Tanzania) 
to identify opportunities for the development of local medical devices. The study found that 
there was a limited local manufacturing capacity and institutional mechanisms to incentivize 
manufacturers to engage in the production of priority medical devices. The same study 
revealed that there was lack of funds for research and development (R&D) and regulatory 
support to bring products into the market and to final users that could be of high public health 
value. Our paper focuses broadly on the persistent challenge of regulating the health sector, 
and particularly the medical devices subsector in developing economy settings where 
capabilities of the regulatory architecture are constrained by many factors relating to 
technological capabilities, market dynamics, actor interactions and firm heterogeneity, 
among others. We do this by analysing and interrogating the evolution and utilisation of 
embedded regulatory capabilities in medical device firms as an opportunity for strengthening 
medical device regulation in capability-constrained environments, using the specific case of 
the South African medical device sector.  
 
2.0 South Africa’s Medical Devices Sector – An Overview 
 
South Africa is the primary business hub for the medical device industry in Sub-Saharan Africa. 
According to Business Monitors International (BMI), the medical device market in South Africa 
is forecasted to grow from $1.3 billion US to around $1.7 billion US by 2021, riding on the 
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strong growth experienced from 2004 to 2013 (BMI, 2016).  Local firms tend to be small or 
medium-sized businesses, with less than 50 employees and often combine distribution 
activities with manufacturing. The South African medical device industry is a highly 
competitive arena where small manufacturers are faced with multiple challenges that cause 
the companies to stagnate or fail (Deloitte, 2014).  
 
Currently a significant proportion of firms that occupy the South African medical device 
industry are multinational corporations (MNCs) such as Johnson & Johnson, Medtronic, GE 
Healthcare, Siemens Healthcare and Philips Healthcare. Typically, these MNCs depend on 
their parent company to develop new products using R&D and regulatory resources housed 
in their headquarters. Few MNCs have in-country control of their product development 
activities, with spending on R&D in South Africa said to be minimal (SAMED, 2016). Most of 
the MNCs present in South Africa often operate in a joint venture capacity with local firms. 
Competing with MNCs is the most significant challenge for local SMEs or start-up 
manufacturers. As a result, they either become subordinate partners to the bigger MNCs, or 
simply sell out and leave the industry (Dawar and Frost, 1999). Those that persist, among 
others, leverage protectionist trade barriers or other forms of governmental support, such as 
local procurement quotas, to survive (Mkwashi, 2020, Maresova and Kuca, 2014) . 
 
Demographic shifts such as ageing populations and technological developments underlie the 
long-term market opportunity for medical device manufacturers in South Africa. It is without 
doubt that the medical devices sector plays a critical role at each stage of the healthcare 
continuum, and has been instrumental in improving access and affordability of healthcare 
services. It is in this backdrop that an investigation into the regulatory constraints and realities 
that have led to a high dependence on imports for addressing domestic demand needs to be 
investigated.  The regulatory constrains are not just for firms, but for the state too.   
 
The main challenge that has been facing the South African government is to institute 
enforceable comprehensive medical devices industry rules, regulations and policies with the 
aim of promoting a national interest that includes the vibrancy of business enterprise 
(Mkwashi, 2020). Prior to 2017, only listed electronic products (also known as 
electromagnetic medical devices or radiation emitting devices) were regulated through the 
Hazardous Substances Act, No. 15 of 1973 and were required to be registered (CE 
certification) before they can be sold, leased, used, operated, or applied in South Africa (Saidi 
and Douglas, 2018). The rest of the medical devices were left unregulated, leaving 
manufacturers, wholesalers or distributors with few legislative formalities with which to 
comply (Mkwashi, 2020). Thus, the drive for improved regulatory systems and the 
establishment of a more effective regulatory framework in South Africa has been evident for 
the past two decades but despite political intentions and legislative revisions success has been 
limited to date (Keyter et al., 2018). In December 2016, the local regulatory framework 
governing medical devices underwent a substantial overhaul, when the Minister of Health 
published the regulations relating to medical devices and in vitro diagnostic medical devices 
(SAHPRA, 2020a). The production and use of medical devices was thereby subjected to a 
number of laws, regulations, strict standards, and certification processes.  
 
2.1 The South African Health Products Regulatory Authority 
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The South African Health Products Regulatory Authority (SAHPRA) is a semi-autonomous 
body established in 2017 by the National Department of Health. It assumed the roles of both 
the Medicines Control Council (MCC) and the Directorate of Radiation Control (DRC) (SAHPRA, 
2020b). SAHPRA was tasked with regulating (monitoring, evaluating, investigating, inspecting 
and registering) all health products. The aim of SAHPRA is to ensure access to safe, effective, 
good quality medical devices, create and maintain an ethical ethos of protecting and 
promoting human health, service excellence and integrity (SAHPRA, 2020b). The country’s 
regulatory framework of medical devices is based on a four-tier, risk-based classification 
system for obtaining device licences for manufacturers, importers and distributors. A novel 
function assigned to SAHPRA was to ensure the periodic re-evaluation or re-assessment and 
monitoring of medicines, medical devices and IVD devices. The continuous monitoring and 
evaluation of the safety, efficacy and performance profile of medical devices provide an 
opportunity for the management of risks throughout the medical device lifecycle. In addition, 
South Africa’s medical device regulations are designed in line with the framework models 
used in developed countries because it was easier to follow the already learned, established 
practice. For example, upon renewal of the SAHPRA licence, manufacturers and distributors 
will have to provide evidence of ISO 13485 certification (SAHPRA, 2020a). Also, the 
requirements for importation and exportation of medical devices are similar to the 
internationally recognised certification programmes of the European CE Mark (Saidi and 
Douglas, 2018). This emerging regulatory environment is key for the performance and 
competitiveness of medical device manufacturers in South Africa, and the health sector 
broadly, hence the importance of analysing regulatory capabilities within the sector. An 
analysis of regulatory capabilities will also deepen understandings of the broader national 
and sectoral systems of innovation, which feed into and draw from the medical devices sector 
through interactions and co-creation of knowledge around products, processes and business 
or organizational models.  
 
3.0 Analysing regulatory capabilities 
 
An analysis of embedded regulatory capabilities is a pertinent undertaking if regulatory 
compliance, a critical issue for all businesses, is to be achieved. Compliance is invariably an 
interplay and interaction among heterogeneous actors operating in specific institutional 
settings. In this paper we investigate the link between capabilities required for regulatory 
compliance, innovation systems and institutions in the specific case of medical devices. This 
paper seeks to enhance academic, policy and practice understandings of the evolution of 
embedded compliance capabilities through a context-specific unpacking of the processes 
underpinning innovation systems and institutions in the medical device sector. The contextual 
details arising from our qualitative analysis allow us to pay adequate attention to structural 
changes, which manifest in the continuous (re)organization of the processes within firms as 
they seek to attain and maintain compliance. 
 
Our departure point is that regulatory compliance is and should not be an onerous or after-
thought activity for firms in this sector, but an integral part of their processes for improving 
performance and enhance competitiveness. Viewed this way, regulatory compliance would 
seek to develop and leverage industry knowledge and regulatory capabilities to inform 
decision making within the firm and the wider ecosystem. There is a case here, as will be 
illustrated by the empirical data we draw from, of integrating regulatory compliance and the 
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requisite capabilities into a business-enhancing strategy for managing regulatory change and 
on-going compliance. The strategy will aim to maximise efficiencies and cost savings, mitigate 
risk of regulatory failure and will harness the best possible ways of ensuring that relevant 
officials in the firm are not only aware of existing and new regulatory requirements, but are 
also able to assess the effectiveness of current compliance frameworks and to benchmark the 
company’s compliance arrangements against established and evolving industry best practice. 
Establishing and deploying policies and procedures for decision making which satisfies 
regulatory requirements and evolving expectations is a key part of the capability mix that is 
required.  
 
The Innovation Systems Approach 
 
The innovation systems lens is important in this analysis in our view of the medical device 
sector as a sector driven by technology and technical change, key drivers of earlier 
Schumpetarian thinking on innovation and development (Cassiolato and Soares, 2015). 
Relatedly, Myrdal (1958)’s proposition that: contexts and institutions matter, positive and 
negative feedbacks have cumulative causation, and cycles may be virtuous or vicious is also 
crucial for our exploration of the dynamics and interactions in this sector. Also central to this 
thinking is Hirschman’s (1958) point that interdependencies among different activities are 
important. Beyond that, the neo-Schumpetarian thinking that innovation is systemic, 
involving interaction among agents, rather than a linear process involving discrete steps, is 
also very important for this analysis as it reveals and locates the interplay between many 
agents, at firm and state levels, inter alia. We are keen particularly on the tacit nature of 
innovation – how it is embedded in people’s minds or in routines and relationships, thus 
revealing how learning-by-doing matters as well as searching for outside technology 
(Lundvall, 2007). This is in addition to the knowledge from formal education systems and the 
wider science and technology (S&T) system, which a technology-intensive sector such as 
medical devices draws from.  
 
Literature has accumulated since the 1970s about how firms acquire and develop 
technological capabilities particularly ‘knowledge and skills required for production (where 
shop floor experience and ‘learning-by-doing’ play an important role) and for investment; as 
well as adaptive engineering and organizational arrangements required for the continuous 
updating of product design and performance features (Dahlman et al., 1987). This work 
showed not only successful stories of technological up-grading, but noted that a learning 
approach to technology ignored key elements, such as the role of institutions and in this 
paper, focus particularly on regulatory capabilities as part of innovation systems and the 
institutions that drive them. Besides filling a gap in literature on studies around regulatory 
capabilities in innovation systems, this paper also uses this case of the medical device sector 
to respond to a gap in the wider innovation systems scholarship, which is the dichotomy of 
how in developed countries, the focus is usually on the evolution and ‘shaping’ of innovation 
systems while in developing countries on ‘construction’ or ‘creation’ of innovation systems 
(Mytelka and Farinelli, 2003). Innovation is a context-specific and socially determined process, 
thus studying and learning from processes is important for both developed and developing 
countries. It is a social process in which most learning occurs locally, with the IS framework 
emphasizing the importance of the territory and local interactive processes. The issues 
discussed in most innovation systems studies underline the importance of understanding the 
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social process that facilitates innovation within a specific territory (the definition of which 
extends beyond geography and considers sectoral, social, economic and political factors). 
Relatedly, development scholars have noted that development is not merely the sum total of 
factors that drive development but is about the processes and interactions between 
“conditions” and “elements” that co-evolve to generate development (Wood, 1994:66). 
Lessons that can be gleaned from the medical device sector will thus be important for both 
innovation systems and development processes broadly. The systemic view inherent in the 
innovation systems framework allows a methodical analysis of the defining elements in the 
medical device sector. Innovation systems consider the entirety of all actors and 
environmental factors that contribute to innovation. The focus of the innovation systems 
approach can be on the level of national innovation systems (Nelson, 1993, Lundvall, 1992), 
regional or local innovation systems (Audretsch, 1995), technological innovation systems 
(Carlsson and Stankiewicz, 1991), or sectoral (Malerba, 2002). The perspective most 
applicable to medical device markets is the sectoral perspective. 
 
Sectoral System of Innovation (SSI) 
 
Breschi and Malerba (1997) state that the sectoral systems of innovation (SSI) is: “that system 
(group) of firms active in developing and making a sector’s products and in generating and 
utilizing a sector’s technologies; such a system of firms is related in two different ways: 
through processes of interaction and cooperation in artifact-technology development and 
through processes of competition and selection in innovative and market activities”. The SSI 
is best suited to describe the dynamics of medical device sector in South Africa for a number 
of reasons. Firstly, the SSI framework in general focuses on supply as well as demand and on 
markets in the innovation process and is build on three pillars: actors and networks, knowledge 
and technologies, and institutions (Malerba and Mani, 2009). The framework selects some 
aspects from the systemic approach to innovation. These aspects are considered crucial 
elements in how the system works overall.  Our study suggests that of these elements, only 
institutions have a predominantly national character. Secondly, the SSI places less emphasis 
on geographic boundaries and devotes greater attention to technologies, product classes and 
innovating firms. These aspects play a crucial role in shaping the South Africa’s medical device 
industry structure and evolution. Lastly, the SSI framework allows for the national, or even 
regional, components of the broader global sector to be envisioned as “sub-sectors”; nested 
within a broader global system of innovation (Malerba, 2005b).  
 
In the SSI perspective it is realised that actors and networks are the heterogenous agents 
composed of individuals or organizations and their interactions. The approach takes the 
sector’s firms which are active in developing and commercialising products, and in generating 
and applying a sector’s technologies, and looks at the processes of interaction with other 
organisations and institutions in the system through the lens of competition and selection in 
the market activities (Malerba, 2004). Firms are typically not only active in a local or national 
geographic area, but increasingly regionally and internationally.  
 
The SSI approach in the health sector has a knowledge base, technologies, input and demand 
where the actors are individuals and organizations at various levels of aggregation with 
specific learning processes, competencies, organizational structure, beliefs, objectives and 
behaviours (Malerba, 2004). Consistent with the evolutionary literature (Dosi, 1997, Nelson, 
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1995), knowledge is a key factor in determining technological change and it is essential for 
innovation. This knowledge is the source of sectoral boundaries and it is dynamic and change 
over time rather than to be fixed (Malerba and Mani, 2009). 
 
The SSI approach considers the institutional framework and the actors in the system as key 
contributors to the system’s dynamics (Caccomo, 1998). The institutions shape and regulate 
the actors’ interactions. The flux in these elements results in a change and transformation in 
the system. Thus the SSI is a dynamic approach and it aligns well with the view that market 
outcomes in the medical device sector are determined by how the actors in the system 
interact under the influence of the institutional framework, particularly with regards to the 
elements of innovation under constraints put up by regulation and regulatory change. The 
fact is established that medical device firms operate in a regulation-intense environment 
which they need to understand and adapt to in order for them to thrive in their business 
(Mkwashi, 2020), and this paper adds to this perspective by taking a close look at the firm-
regulation interface in South Africa from the point of view of firms as key actors in the 
regulatory system. We will argue that a clearer understanding and ability by the firms to 
navigate knowledge systems at play in the sector, especially in an environment of economic 
and market heterogeneity and uncertainty such as South Africa, will enable the regulatory 
infrastructure to be able to help create and sustain a mutually-beneficial firm-regulation 
interface.  
 
3.1 Regulatory capabilities – what are they? 
 
As innovation occurs, it is important that regulatory professionals stay relevant and have the 
necessary skills and competencies to make substantive contributions to their organisations 
(Drago et al., 2017). The UK government developed a guidance framework that can be used 
to analyse and assess core regulatory competences (see Figure 1). Core or generic 
competencies in the medical device sector would be those that are specific to the regulation 
of medical products, spanning all the regulatory functions. This is important to support the 
development of an agile workforce and facilitate movement not only between regulatory 
functions, but also between sectors, e.g., from industry to government and vice versa (World 




Figure 1. Core regulatory competencies framework.  
Source: https://www.gov.uk/guidance/core-competencies-for-regulators 
 
We adapt and deploy the framework above to represent not only a tool for national 
regulatory authorities (NRA) development, but also a continuum of the NRA’s capabilities in 
performing regulatory functions on behalf of the state. Thus, the competency framework for 
regulators allows competency modelling by individual NRAs and aligns individual capabilities 
with the organizational strategy and business processes (World Health Organization, 2019). 
Our argument in this paper is that such a framework concomitantly gives clarity and direction 





In order to provide some valid and reliable scientific claims from the research process, a 
mixed-method approach was used (Bryman, 2007). Mixed methods, in which quantitative and 
qualitative methods are combined, are increasingly recognized as valuable, because they can 
capitalize on the respective strengths of each approach (Jick, 1979, Tashakkori and Teddlie, 
2010). The main method of collecting primary data for this study was semi-structured in-
depth interviews with South African medical device sector key stakeholders. The categories 
of respondents included medical device manufacturers, government officials, regulatory 
agencies, academic and research institutions and industry associations. These interviews 
allowed the researchers to gain a deeper understanding of the competitive forces 
experienced by firms in the medical device industry, the limitations within the industry, the 
obstacles faced by firms in developing and deploying regulatory capabilities and key success 
factors in the firm’s survival and growth. A total of 48 interviews were conducted during a 
 8 
field study between October 2016 and May 2017 and these interviews, augmented by regular 
updates and follow-up after the field study period, provide the basis for the analysis and 
narrative underpinning this paper. In addition to this being the first extensive study of this 
nature covering out focus country, this study also chose South Africa for the following 
objective reasons: firstly, it is one of the African Biomedical Engineering Consortium (ABEC) 
countries that has implemented or harmonized with European directives in its legislation, 
despite the fact that the legislation is particularly strict (De Maria et al., 2018). Secondly, the 
legislative framework of South Africa adopted the International Medical Device Regulators 
Forum (IMDRF) philosophy of accelerating international medical device regulatory 
harmonization and convergence (IMDRF, 2020). Thirdly, South Africa adopted the Risk 
Classification System formulated by the Global Harmonization Task Force (GHTF) that has 
drawn the interest of policymakers and regulators in many countries.   
 
Ethical considerations were vital in the conduct of this research as it involved collection of 
data from people and organizations. Ethics approval was thus obtained from the Open 
University’s Ethics Committee for all phases of the research. Necessary steps for ensuring 
anonymity and confidentiality were designed into the research schedule. Prior to the 
interviews, informed consent to participate in the interview was obtained from each 
interviewee as outlined in the ethical procedure spelt out from the Open University Ethics 
Committee.  
 
Thematic analysis (Boyatzis, 1998) was used for analysis and interpretation of the largely 
qualitative data that was collected for this study. NVivo software was used to aid data 
management, and its organisation into codes, categories and themes. Our analysis of findings 
below situates the views of respondents on regulatory capabilities in the context of 
interactions between firms and the state, within the framework shaped by the emerging 
regulatory environment for medical devices.  
 
5.0 Findings and Analysis 
 
Regulation as a defining institutional element of the sectoral systems of innovation 
 
In the sectoral systems of innovation institutions include norms, routines, common habits, 
established practices, rules, laws, standards, etc. These institutions affect the actions, 
cognition and interactions of sector participants (Malerba, 2005a)1. Similarly, Furubotn and 
Richter (2005) echoed that the way in which actors in the sectoral system participate and 
contribute to innovation is affected by the environment in which innovation takes place. It is 
important to realise that institutions do matter, and time does as well. While regulation 
typically encompasses codified law and non-codified structures in medical devices, the 
codified rules determine the entry of new products and technologies to the market2. Different 
studies have drawn attention to the effects of regulations; on one hand research has 
highlighted that regulations have forced firms to focus more on innovation capability to 
comply with regulations and on the other hand this has become a barrier for firms leading to 
 
1 Regulation in this context is only one element of the institutional framework within which the innovation 
system operates. 
2 Regulation encompasses not only the codified rules, but also the standards that actors in the market are 
expected to adhere to. 
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their exit. Our findings highlighted that regulations play a major role in affecting the rate of 
technological change, the organization of innovation activity and performance. Our findings 
further confirm that whilst the state, through competent authorities, seeks to ensure that the 
requirements of the regulations are applied, the extent to which this is feasible is dependent 
on the manufacturing firm’s capabilities to respond and deploy the new regulatory 
environment. Teece et al. (1994, p.18) define these capabilities as “a measure of the firm’s 
ability to solve both technical and organizational problems”. The firm-level technological 
capabilities therefore determine what the firm is potentially able to do in response to the new 
regulatory demands. In tables 1 and 2 below, we draw from our data to present a comparison 
of required and available capabilities in MNCs and local firms.  
 
• What respondents say about the regulatory capabilities required and available 
 
 
Table 1: Levels of importance and availability of capabilities in MNCs 
MNCs 
 Regulatory capabilities Level of importance 
of capability 
Level of availability 
of capability in firm 
R&D investment Medium Medium 
Recruitment and training High High 
Innovation in production Medium Medium 
Compliance capability High High 
Risk management capability High High 
Quality Control capability High High 
Linkages between firms  High High 




Table 2: Levels of importance and availability of capabilities in SMEs 
SMEs 
 Regulatory capabilities Level of importance 
of capability 
Level of availability 
of capability in firm 
R&D investment High Low 
Recruitment and training High Low 
Innovation in production Low Low 
Compliance capability High Low 
Risk management capability High High 
Quality Control capability High High 
Linkages between firms  High High 




From the above tables, we can deduce that while the different capabilities are important for 
both large and small firms, their availability is limited in the small firms, limiting the overall 
regulatory capability in these firms, which in turn limits their ability to comply with the 
regulatory requirements. As highlighted by other scholars, for example (Nkambule, 2018), the 
factors that lead to low regulatory capabilities in small firms in particular and developing 
countries broadly, relate to the lack of appropriately qualified, trained and experienced 
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regulators in the competent authority and in the firms.  For example, some respondents 
highlighted that, SAHPRA inherited employees from the MCC, whose expertise is in the 
regulation of medicines, therefore, a shortage of skilled personnel to attend specifically to 
medical devices was likely, unless staff recruitment was to be undertaken and in-house 
training was to be put in place. Recognising this, SAHPRA has been encouraging a “capacity 
building” component in a clinical trial application process, a thrust that speaks directly to the 
national imperative for enhancing regulatory capabilities in South Africa (Nkambule, 2018). 
Further, as a competent authority, SAHPRA does seem to acknowledge that to successfully 
implement medical device regulations, stakeholders in the medical device industry 
collaborate. Our data points to the need for manufacturers to have embedded capabilities  
(i.e. the necessary expertise and experience) in order for them to know how to execute the 
regulations. Thus, the proactive engagement of different stakeholders from the medical 
device industry as partners in the implementation of the regulations would be beneficial to 
the sector. 
 
Actors and Networks as sources of regulatory capabilities in South Africa’s medical device 
sector 
 
The term “actors” used in the innovation literature refers to both groups of individuals and 
organisations operating within the system or sector of interest. These actors could include 
consumers, entrepreneurs, scientists, firms, universities, financial institutions, government 
departments, etc. Sub-groups, such as departments within firms, can also be regarded as 
actors (Malerba, 2005a). South Africa-based medical device firms are key actors in innovation 
and production in the sectoral system. These firms are characterized by specific learning 
processes, capabilities, competencies and organizational structures, as well as by beliefs and, 
expectations and goals (Nelson and Winter, 1982, Teece and Pisano, 1994, Dosi et al., 2000). 
Within South Africa’s medical device sector, firms are connected in various ways through 
market and non-market relations. Thus, relationships between firms and non-firm 
organizations (such as universities and public research centres) have been a source of 
innovation, regulatory capabilities and change in the sectoral system. 
 
• What respondents say about sources of regulatory capabilities 
 
In Table 3 below, we summarise our findings on the diverse sources for the capabilities that 
are required by both the state and firms to ensure compliance with regulations.  
 
Table 3: Sources of regulatory capabilities in South Africa’s medical device sector 
                                             Sources of capabilities in SA 
 Regulatory capabilities MNCs SMEs 
R&D (Investment, Design 
concept, Develop concept 
and Prototype 
development) 





- Venture capitalists 
 - Incubators 
 - Government 
- Academia 
-MNCs 
- Industrial Development Corporation 
- Banks 
- Other investors  
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- Role of MNCs 
- SANAS  
- Established academic institutions  
Innovation in production 
(Device design, Clinical 
trials and field testing and 
manufacturing) 
- Role of SMEs 
- MCC/SAHPRA 
- South African Bureau of 
Standards (SABS) 






- Regulatory agencies 
- Strategic Health Innovation 
Partnerships (SHIP) 
- Global Health Innovation 
- Accelerator (GHIA) 
- Industrial Development Corporation 
-Banks 
- Venture Capital investors 





- Regulatory agencies  




- Policy formulators and 
implementers. 
- Risk management 
standard ISO 14971. - 
Essential Principles of 
Safety and Performance 
documents. 
- Code of Practice for 
industrial radiography 
- Policy formulators and 
implementers 
- Risk management standard ISO 
14971 
- Essential Principles of Safety and 
Performance documents 
- Code of Practice for industrial 
radiography 
Quality Control capability - Quality management 
standards e.g. ISO 13485 
and ISO 9001 
Quality management standards e.g. 
ISO 13485 and ISO 9001 
Linkages between firms  - Resources from external 




- Resources from external partners 
such as MNCs, start-ups, critical 
subcontractors & crucial suppliers. 









From the table, we can argue that the sources and support for medical device firms’ as well 
as state regulatory capabilities can be viewed in the context of the medical device life cycle. 
Launching a medical device in South Africa was highlighted to be a challenging process, 
involving several steps that ensure the product meets all regulatory requirements. Medical 
device incubators and accelerators help start-ups while small businesses develop and take 
products to the market. Networking opportunities and capabilities are this valuable for these 
actors, to enable them to access funding, innovation support and other resources to build 
infrastructure and get ideas transformed into reality. Both the state and firms, with support 
from intermediary bodies, have got a role to play in creating the spaces and opportunities for 
collaboration, co-creation of and co-evolution towards the required capabilities.  
 
The practice of regulating medical devices effectively and efficiently requires appropriate 
individual expertise, reinforced by the institutional capacity of the regulatory authority, to act 
according to good regulatory practices (WHO, 2017). Governments have a key role to play in 
promoting, directing and accelerating the learning process (Nübler, 2014). Policies to 
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promote the development of productive and embedded regulatory capabilities relate to 
different areas and require a comprehensive and coordinated strategy. South Africa has 
established institutions that can be used as sources for biomedical/clinical engineering 
education and research as well as training programs for medical device technicians. For 
example, biomedical/clinical engineering training exists at the leading South Africa’s 
universities such as Tshwane University of Technology, University of Cape Town, University 
of Stellenbosch, and Witwatersrand University (WHO, 2015). The Clinical Engineering 
Association of South Africa also provides training to medical device technicians (CEASA, 2018). 
The role of the government is also significant in ensuring support for local production, but 
equally critical is the role of academia to train biomedical engineers, clinical engineers, 
regulatory science professionals and other professionals capable of translating local needs 
into action and finding appropriate local solutions based on international best practices. It is 
generally agreed that while beneficial in some respects, South Africa’s institutional context 
has historically not provided an environment conducive to research and development for 
novel medical devices and also contributed to the underdevelopment of the country’s 
medical device regulatory capabilities (De Maria et al., 2018). 
 
MNCs are involved in discovery and commercialization processes. The special role of large 
companies is to contribute infrastructure, market knowledge, and financial resources to 
validate technologies and make them valuable to patients (Pope et al., 2001). These MNCs 
have the ability to bring scale to the challenge of globalization and successful product 
development. Furthermore, MNCs can supply capital and credibility. With the exception of 
large medical device firms, few SMEs have the ensemble of regulatory capabilities. Indeed, 
even large firms are increasingly outsourcing much of the innovative activities to specialized 
firms. Therefore, related innovations provide an opportunity for the often-distinct expertise 
and actors to pool their knowledge, and other resources, to develop a given product. In fact, 
MNCs are already playing a key role in SA in the growth of the medical device industry through 
acquisitions, joint ventures, strategic alliances, contract research, licensing and royalty 
agreements (Mkwashi, 2020). 
 
International quality standards are also good sources of regulatory capabilities. They have 
been applied to the design, manufacturing and distribution of medical devices. Such 
standards are aimed at ensuring that customers receive products that meet both regulations 
and safety expectations (Cheng, 2003). For example, compliance with the ISO 13485 quality 
management system, which prioritises risk reduction and safety, is a requirement for 
producing medical devices with a risk classification above Class I (Mitra, 2016). The local 
manufacturers of radiation emitting devices in SA have also learned to adopt the “Code of 
Practice for industrial radiography - X-ray Equipment” as an embedded regulatory mechanism 
to manage potential risks. 
 
The role of medical device industry associations is to advocate for innovation and to help its 
member companies move through the regulatory and public policy processes. Because 
regulation is the result legislation to affect change either in the regulatory process or within 
public policy, industry associations and researchers need to be players in the broader policy 
and political debates (Pope et al., 2001). Due to the changing pattern of government and 
industry relationships, information sharing and collaboration become essential or 
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unavoidable and this impacts on the manner in which the innovation process is organized 
(Malerba and Adams, 2014, Mkwashi, 2020). 
 
Critical subcontractors and crucial suppliers are also other import sources and support for 
medical device firms’ regulatory capabilities. The critical subcontractors ensures all or part of 
the medical device's design, or performs all or part of the manufacturing processes, or carries 
out all or part of an activity in relation to regulatory requirements (e.g. post-market data 
collection).  Crucial suppliers on the other hand provide finished devices, or key sub-
assemblies essential to the performance of the medical device, or critical raw materials.   
 
• Constraints for obtaining and sustaining the capabilities 
 
In this study, we examine regulatory constrains for obtaining and sustaining capabilities by 
analysing regulatory design. In Table 4 below, constraints for both the state and firms are 
summarized and organized according to the three categories (Lack of knowledge, willingness 
to comply, and ability to comply).  
 














SMEs -Requirements are too 
complex to know and 
understand. 
 
-Voluntary compliance is 
low when costs (in time, 
money, or effort) are 
considered to be high. 
- Most firms seem to 
view regulatory agencies 
as a police officer rather 
than a partner. 
-Costs of Compliance. 
SMEs disproportionately 
high for SMEs based on 
their size and turnover, 
and affect SME 
compliance rates. 
- Failures of 
administrative capacity 
-Bureaucratic protocols 




regulation in the form of 
failure to consider 
arguments by regulated 
enterprises. 
- Failures of prior 
consultations with firms 
-Lack of calibration 
authorities. 
- Significant delay in 
research ethics approval 
 
Regulators Regulator dependence 
on over-committed 
external expertise 
 -Limited local capacity 
for auditing facilities. 
- Failure to monitor 
regulatory compliance 
as regulators have relied 
on self-regulation or co-
regulation with the aim 
of increasing voluntary 
compliance. 





SMEs play an important role in the product development ecosystem, but SMEs in South Africa 
are often struggling with the regulatory complexities of the medical devices development 
cycle. Most of the industry stakeholders confirmed that regulatory requirements are too 
complex to understand and compliance costs are generally higher for SMEs, suggesting that 
there is a higher risk of compliance failure. If the costs of compliance appear 
disproportionately high compared with the potential of a market, or if regulatory 
requirements are not harmonized with those of other countries, manufacturers and 
importers may be discouraged from offering their products and that may impede 
achievement of national public health goals (WHO, 2017). 
 
A majority of SMEs argued that the bureaucratic protocols caused by the regulatory 
environment slowed the process of innovation and their ability to comply. These firms stated 
that there are lots of documentations and administrative procedures to bring a product in to 
the market that inevitably impede innovative outputs. Most firms seem to view regulatory 
agencies as a police officer rather than a partner, thus affecting their willingness to comply 
with regulation. 
 
One of the biggest regulatory constraints in SA is lack of calibration authorities. Calibration 
according to SANAS means a set of operations that establish, under specified conditions, the 
relationship between values of quantities indicated by a measuring instrument or measuring 
system, or values represented by a material measure or reference material, and 
corresponding values realised by standards whatever their uncertainty. The respondents 
highlighted that if they have equipment that might need to be calibrated, the firms will have 
to send the equipment oversees and this process is very expensive. 
 
Some MNCs highlighted that there is an overly legalistic regulation in the form of failure to 
consider arguments by regulated enterprises. These MNCs echoed that, SA is an attractive 
location for conducting clinical investigations in Africa. However, delays in the ethics approval 
process, estimated at six months on average, are thought to be a significant stumbling block 
preventing the industry from reaching its potential in clinical research. The involvement of 
multiple bodies, such as Southern African Radiation Protection Association (SARPA), the 
Medical Research Council (MRC) Ethics committee and Radiation Control Directorate (RCD) 
are contributing factors to these delays, with the last two perceived as primarily responsible. 
 
Historically SA’s Medicines Control Council (MCC), which was superseded by SAHPRA, faced 
resource constraints as workloads placed on the regulator steadily increased. As a result the 
MCC became dependent on over-committed external expertise. Evaluation structures which 
relied on external evaluators lacked effective performance management contracts and did 
not provide a sustainable mechanism for timely submission of evaluation reports (Keyter et 
al., 2018).  
 
In Table 5 below, we draw from our empirical findings to illustrate some examples of where 
embedded capabilities have proved helpful in the South African medical device sector. 
 
























- The establishment 
of Regulatory 
Compliance unit of 
SAHPRA responsible 











- Firms that 
embraced quality 
had fewer negative 
events to address 
- QC tests played 
an important role 
in diagnostic 












industry actors and 
facilitated growth 
of the industry 
 
 
There are a number of ways in which embedded regulatory capabilities and regulatory 
processes for medical devices in SA have proved helpful and improving. These include the use 
of advisory groups within regulators that can bring data, insight and knowledge to the medical 
device development ecosystem, expedited reviews for breakthrough and highly beneficial 
innovations, early interactions and consultations on new regulatory changes, reducing 
inspection burdens on companies with an excellent compliance track record, increased access 
particularly for SMEs and better coordination within MCC/SAHPRA with respect to 
combination products. 
 
 The establishment of Regulatory Compliance unit of SAHPRA has proved helpful in 
monitoring and control of border posts for imports and exports of health products, preventing 
and monitoring of unregistered health products, counterfeits, substandard and 
falsified medical devices (SAHPRA, 2020b). This embedded regulatory capability has also 
helped in the monitoring and eradicating emerging illegal retail outlet selling of healthcare 
products and stopping the illicit manufacturing facilities and ensuring that unregistered 
healthcare products are removed from the public. SAPHRA is now using a risk-based approach 
that seeks to channel available resources to regulatory functions and activities that are most 
likely to facilitate access to quality-assured products and identify and address high-risk quality 
problems, thereby maximizing the impact of regulatory investments.   
 
SANAS entered the market as control actors and certifiers of manufacturers’ quality 
management system (QMS), a central role in SA’s radiation emitting device regulations. The 
embedded capabilities in the SANAS annual quality control (QC) tests include preventive 
maintenance procedures, administrative methods and training. They also include continuous 
assessment of the efficacy of the imaging service and the means to initiate corrective action 
(Fiedler, 2017). Most of stakeholders in SA were in agreement that the introduction of the QC 
tests has played an important role in diagnostic imaging to limit the population dose growth, 
thereby improved quality control. The inspection of facilities involved in product 
development and along the supply chain is integral to assure the quality of medical products. 
Inspections conducted in accordance with international standards, norms, and guidelines 
reveal weaknesses and deficiencies as well as actual or predictable errors in production, 
quality control, storage, or distribution (WHO, 2018). 
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In the past the MCC did not have a dedicated Quality Management Unit, however, 
contingencies have been put in place to establish such a unit. This unit is responsible for 
formalizing the implementation of the QMS for the authority and for performing internal 
quality audits and for implementing strategies geared for continuous improvement. Through 
the application of a robust QMS underpinned by the drive to cultivate an integral quality 
culture the regulatory performance and responsiveness of SAHPRA has been enhanced. 
 
Discussion  
In this section, we discuss our findings on various key aspects around key themes on 
embedded regulatory capabilities as set out in our conceptual and methodological process 
and empirical findings above. As highlighted, this study makes an argument that a strong 
understanding among actors and ability to navigate knowledge systems at play in the sector, 
especially in an environment of heterogeneity and uncertainty such as South Africa, will 
enable the regulatory infrastructure to be able to help create and sustain a mutually-
beneficial firm-regulation interface. 
 
Knowledge requirements for regulatory policy execution 
 
The knowledge base of a sector plays a central role in innovation and greatly affects the types 
of learning and capabilities of firms (Malerba and Mani, 2009). With respect to the nature of 
the underlying knowledge within the SSI framework, factors such as specificity, tacitness, 
complexity, independence, and the means of knowledge transmission are viewed to play an 
important role in a regulatory regime (Malerba, 2005b).  For many years, South Africa 
government has faced dynamic complex issues that prevented the achievement of optimal 
regulatory implementation. Some of these issues are due to the knowledge requirements 
needed to execute regulatory policies effectively. However, knowledge is highly idiosyncratic 
at the organizational or firm level, does not diffuse automatically and freely among actors, 
and has to be absorbed by organizations or firms through their differential abilities 
accumulated over time (Malerba and Mani, 2009). Therefore, having an awareness of the 
context under which regulatory capability develops would be a big advantage and let the 
organization gradually build its knowledge-based system (Alrabiah and Drew, 2020). The 
development and application or regulations calls for a well-trained, scientifically engaged and 
motivated workforce. Hawkins (2000) argued that insufficient knowledge and inadequate 
information of regulators can be threats to regulatory processes. Regulators are supposed to 
not only have a deep understanding of the role regulation play as a tool of government but 
also have the understanding of the role and responsibilities of partner organisations. 
Regulators must be able to work within the wider regulatory framework, work towards 
regulatory objectives, and within regulatory policies and procedures. Our case study results 
revealed that the efficacy of regulators depend on their knowledge, and that this is positively 
related to the knowledge possessed by the regulated firms. Our case study further illustrates 
how enabling regulation serves both as the legislative mandate for the competent authorities 
to act, and as a starting point for these regulators’ discretion and oversight. The enabling 
content will allow for the control and the evaluation of the performance of the regulation. 
The latter can only be carried out where a well-defined and focused set of objectives in the 





Effective local regulation depends upon the regulators’ ability to assess regulatory risks and 
the understanding of risk management in a business context. Risk Assessment evaluates the 
likelihood and potential severity of significant risky outcomes, and it uses that analysis to 
place the situation into crude categories of “ high, ” “ medium, ” and “ low ” risk (Weinberg, 
2011). By basing their regulatory work on an assessment of the risks to regulatory outcomes, 
regulators are able to target their resources where they will be most effective and where risk 
is highest (BERR, 2007). As such, in order to carry out comprehensive and effective risk 
assessment, regulators must ensure that risk assessment precedes and informs all aspects of 
their approaches to regulatory activity such as inspection programmes, advice and support 
programmes, and enforcement and sanctions. Herbst and Fick (2012), whose study focused 
on SA regulation, radiation protection and the safe use of X-ray equipment indicated that 
poor risk management of regulatory system, lack of financial resources and deficient human 
regulatory capacity put the health and safety of the local population at risk. As such, risk 
assessment should include explicit consideration of the combined effect of the potential 
impact of non-compliance on regulatory outcomes; and the likelihood of non-compliance 
(BERR, 2007). 
 
Understanding those you regulate 
 
Regulators within the scope of core regulatory competencies framework are diverse but they 
share a common primary purpose – to regulate for the protection of the vulnerable, the 
environment, social or other objective. Regulators should have an understanding of the 
current business environment and the business sector(s) regulated. South Africa’s current 
business environment has developed a distribution infrastructure based primarily on-
imported medical devices and for a long time had limited regulation requirements. 
Furthermore, five out of seven new small businesses in South Africa fail within their first year 
(Leboea, 2017). Therefore, to have an effective regulatory framework, SA regulators must 
have an ability to engage constructively with business and an ability to tailor their approach 
to businesses and individuals that they interact with taking into consideration the fact that it 
is mainly an importer’s market. From 1973 to 2017, the country was relying only on the 
regulations concerning the use of X-ray equipment in terms of the 1973 Act. The South African 
medical device sector is now in a transition phase and importantly, the end of the transition 
period will not mark a point when the regulatory environment for medical devices is 
complete, for managing such a large and vast field as medical devices will always be work in 
progress, but it will nevertheless introduce a considerably higher level of quality to the 
management of medical devices in SA than ever before.  
 
When designing and reviewing policies, operational procedures and practices, regulators 
should consider how they might support or enable economic growth for compliant businesses 
and other regulated entities (Hodges, 2020). They should ensure that their officers have the 
necessary knowledge and skills to support those they regulate. Regulators must have a clear 
understanding of how regulation and the way it is enforced can impact on the business 
communities and individual businesses. Our analysis has shed light, with the help of pre-
existing literature, on the way in which different types of regulatory approaches can affect 
firm level capabilities. In our case study for example, we found that a more prescriptive, rigid 
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regulatory change can hamper innovative activity by reducing the attractiveness of engaging 
in R&D, constraining modes of commercialization, and creating lock-in effects that force the 
economy into suboptimal standards.  
 
Understanding the co-evolution of the regulatory regime (state) and firm-based institutional 
capabilities 
 
The general, the extent and nature of state intervention in the economy is a live discourse in 
the literature (Wong, 2005). Firm capabilities and state regulation are inseparable, emerge 
and co-evolve, they represent the behaviors that follow from rules and norms (Schotter, 
2008). Viewed from a sectoral systems of innovation perspective, it is clear that the state is 
almost always involved in the innovation process, if only by virtue of its effect on the 
institutional environment and/or support for R&D activities (Malerba and Mani, 2009). The 
regulatory regime must therefore understand that, the opportunity provided to private actors 
such as MNCs to participate in the regulatory process, share information and collaborate, 
contributes to the improvement of their knowledge. In turn, improved knowledge increases 
the innovative potential of actors while it builds their bargaining power and increases the 
possibilities private actors have to influence their institutional environment (Pietrobelli and 
Rabellotti, 2011). 
 
Planning Regulatory activities 
 
Regulators ought to carry out their “regulatory activities”3 in a way that supports those they 
regulate to comply and grow. Regulators should avoid imposing unnecessary regulatory 
burdens through their regulatory activities and should assess whether similar social, 
environmental and economic outcomes could be achieved by less burdensome means 
(Hodges, 2016). Regulators should choose proportionate approaches to those they regulate, 
based on relevant factors including, for example, business size and capacity. De Maria et al. 
(2018) conducted a study aimed at comparing the certification route that manufactures must 
respect for marketing a medical device in some African Countries and in European Union. The 
study found that in developing countries, poor regulatory control results in the use of 
substandard devices, and often it becomes a constraint for those wanting to produce, sell, or 
even donate these devices. Similarly, (Saidi, 2016) explores the importance of medical device 
regulation in promoting access to high quality, safe and effective medical devices. The study 
emphasizes that medical device regulation in developing countries helps to prevent the 
importation and use of substandard devices thereby protecting the users from falling prey to 




Regulators should publish a set of clear standards, including a compliance and enforcement 
policy. These standards should clearly set out what businesses and regulated bodies should 
be able to expect from regulators. Standards should cover areas including providing advice 
 
3 The term ‘regulatory activities’ refers to the whole range of regulatory options and 
interventions available to regulators. 
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and other support for compliance, responding to stakeholder views, setting fees and charges 
and the professional competency of officers. Service standards, including compliance and 
enforcement policies, should be published and easily accessible, including on the regulator’s 
website, and clearly “labelled‟ as to when they were last reviewed and the date of the next 
review. Inspections can be an effective approach to achieving compliance, but are likely to be 
most effective when they are justified and targeted on the basis of an assessment of risk. In 
order to ensure the effectiveness of their inspection programmes, regulators should focus 
their greatest inspection effort on regulated entities where risk assessment shows that both, 
a compliance breach or breaches would pose a serious risk to a regulatory outcome, and there 
is high likelihood of non-compliance by regulated entities (BERR, 2007). By facilitating 
compliance through a positive and proactive approach, regulators can achieve higher 
compliance rates and reduce the need for reactive enforcement actions. However, regulators 




State regulation and firm innovation processes are evolutionary processes that interact 
overtime and their co-evolution is facilitated by knowledgeable actors who wish to influence 
their institutional environment. Regulators must, therefore, have an ability to evaluate their 
activities in relation to their regulatory objectives and their organisation’s strategic priorities. 
Evaluating regulatory activities entails an inquiry, after regulation has been put in place, into 
how it has changed behaviour as well as, ultimately, its impacts on conditions in the world 
(Coglianese, 2012). Regulators should have an understanding of the value of feedback from 




Regulatory authorities in developing economies not only face challenges regarding their own 
capabilities, but also have to grapple with heterogeneous levels of technological and 
innovation capabilities in firms. This paper draws from a firm-level analysis of internally 
created knowledge, externally sourced knowledge and firm heterogeneity among medical 
device manufacturers in South Africa to consider the corresponding evolution, development 
and deployment of regulatory capabilities in firms in their efforts to comply with the country’s 
health and allied products regulatory authority requirements. Our departure point is that 
regulatory compliance is and should not be an onerous or after-thought activity for firms in 
this sector, but an integral part of their processes for improving performance and enhance 
competitiveness. Viewed this way, regulatory compliance would seek to develop and leverage 
industry knowledge and regulatory capabilities to inform decision making within the firm and 
the wider ecosystem. There is a case here, as illustrated by the empirical data we drew from, 
of integrating regulatory compliance and the requisite capabilities into a business-enhancing 
strategy for managing regulatory change and on-going compliance. The strategy will aim to 
maximise efficiencies and cost savings, mitigate risk of regulatory failure and will harness the 
best possible ways of ensuring that relevant officials in the firm are not only aware of existing 
and new regulatory requirements, but are also able to assess the effectiveness of current 
compliance frameworks and to benchmark the company’s compliance arrangements against 
established and evolving industry best practice. Establishing and deploying policies and 
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procedures for decision making which satisfy regulatory requirements and evolving 
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